Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney

Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGL...

Descripción completa

Detalles Bibliográficos
Autores principales: Giugliano, Dario, De Nicola, Luca, Maiorino, Maria Ida, Bellastella, Giuseppe, Garofalo, Carlo, Chiodini, Paolo, Ceriello, Antonio, Esposito, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081614/
https://www.ncbi.nlm.nih.gov/pubmed/32192503
http://dx.doi.org/10.1186/s12933-020-01010-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081614/
https://www.ncbi.nlm.nih.gov/pubmed/32192503
http://dx.doi.org/10.1186/s12933-020-01010-x

Ejemplares similares